Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level

Effects of Different Progesterone Containing Contraceptive Methods on Safety and Endogenous Progesterone Level

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05742503

Enrollment

Registered

2023-02-24

Start date

2021-03-30

Completion date

2022-03-30

Last updated

2023-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progesterone, Contraceptive Methods

Brief summary

The aim of this study is to assess the effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level

Detailed description

Progestogen-only' contraceptives are presented as injections, implants, oral formulations, hormone-releasing intrauterine methods and emergency contraceptives. These substances could be used by females who are breastfeeding or have other contraindications to estrogen treatment, including those who are immediately postpartum, have thalassemia, sickle-cell disease, gallbladder disease, or currently experiencing thrombo-embolic disorders, valvular heart disease, ischemic heart disease. Intrauterine, injectable methods and contraceptive implants named as long-acting reversible contraceptives (LARC) are the more efficient reversible contraceptive approaches are highly effective, longer-acting contraceptive methods levels.

Interventions

OTHERDepo-Provera

Injectable progesterone

OTHERImplanon

Etonogestrel implant

OTHERNorgestrel

Pill containing progesterone

OTHERMirena

Levonorgestrel-releasing intra-uterine drug (IUD)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* 80 healthy fertile females * 20-35 years * With normal menstrual history * Had at least one offspring after spontaneous pregnancy

Exclusion criteria

* Any disease affects uterus (uterine tumors fibroids, endometriosis, prolapse, or tuberculosis). * Ovarian tumors * submucous myoma * irregular menstrual cycle * past or family history of breast disease * Diabetic patients, * medication affecting reproductive or metabolic functions. * endometrial thickness \<7 mm on the secretory transformation day * history of spontaneous abortions * history of embryo transfer failure on over three occasions * Patients had cortisol medications * patients who received radiological treatment

Design outcomes

Primary

Measure	Time frame	Description
Assess the effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level	Six mounths	The effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level will be recorded

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026